Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.97 HKD | 0.00% | -9.35% | -51.50% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-51.50% | 83.8M | - | ||
+5.33% | 111B | B+ | ||
+12.11% | 106B | B+ | ||
-12.56% | 22.24B | B+ | ||
-3.46% | 21.25B | B | ||
-5.85% | 18.97B | A- | ||
-35.21% | 18.52B | A- | ||
-10.86% | 16.81B | B | ||
+37.57% | 12.54B | C+ | ||
-26.24% | 8.09B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6996 Stock
- Ratings Antengene Corporation Limited